Skip to content
Back to outputs

Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998

Research output: Contribution to journalArticle

Standard

Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998. / Yu, Cheng-yin; Liu, Gang-yi; Liu, Xiao-hui; Gui, Yu-zhou; Liu, Hai-ming; Zheng, Hong-chao; Gorecki, Darek; Patel, Asmita Vithaldas; Yu, Chen; Wang, Yi-ping.

In: Acta Pharmacologica Sinica, Vol. 39, 01.09.2018, p. 1473-1482.

Research output: Contribution to journalArticle

Harvard

Yu, C, Liu, G, Liu, X, Gui, Y, Liu, H, Zheng, H, Gorecki, D, Patel, AV, Yu, C & Wang, Y 2018, 'Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998' Acta Pharmacologica Sinica, vol. 39, pp. 1473-1482. https://doi.org/10.1038/aps.2017.200

APA

Yu, C., Liu, G., Liu, X., Gui, Y., Liu, H., Zheng, H., ... Wang, Y. (2018). Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998. Acta Pharmacologica Sinica, 39, 1473-1482. https://doi.org/10.1038/aps.2017.200

Vancouver

Yu C, Liu G, Liu X, Gui Y, Liu H, Zheng H et al. Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998. Acta Pharmacologica Sinica. 2018 Sep 1;39:1473-1482. https://doi.org/10.1038/aps.2017.200

Author

Yu, Cheng-yin ; Liu, Gang-yi ; Liu, Xiao-hui ; Gui, Yu-zhou ; Liu, Hai-ming ; Zheng, Hong-chao ; Gorecki, Darek ; Patel, Asmita Vithaldas ; Yu, Chen ; Wang, Yi-ping. / Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998. In: Acta Pharmacologica Sinica. 2018 ; Vol. 39. pp. 1473-1482.

Bibtex

@article{f35fb0fd4584475fbd7a569710d57f02,
title = "Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998",
abstract = "Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.",
author = "Cheng-yin Yu and Gang-yi Liu and Xiao-hui Liu and Yu-zhou Gui and Hai-ming Liu and Hong-chao Zheng and Darek Gorecki and Patel, {Asmita Vithaldas} and Chen Yu and Yi-ping Wang",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/aps.2017.200",
language = "English",
volume = "39",
pages = "1473--1482",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Proteomics analysis reveals a potential new target protein for lipid-lowering effect of Berberine8998

AU - Yu, Cheng-yin

AU - Liu, Gang-yi

AU - Liu, Xiao-hui

AU - Gui, Yu-zhou

AU - Liu, Hai-ming

AU - Zheng, Hong-chao

AU - Gorecki, Darek

AU - Patel, Asmita Vithaldas

AU - Yu, Chen

AU - Wang, Yi-ping

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.

AB - Aims - The objective of this study was to investigate the effect of a berberine derivative, berberine8998, on serum cholesterol and lipid levels in-vivo and to explore the mechanisms involved.Methods - Lipid lowering effect of berberine and berberine8998 was determined by high fat diet model on hamsters. Total cholesterol, low-density lipoprotein and triglycerides were analyzed. The potential target proteins on hamster liver were screened by iTRAQ labeled proteomics. The effect of berberine and berberine8998 on ACOX1 and ACSL1 was determined by western blot. Non-esterified fatty acids were analyzed to demonstrate its effect on triglyceride and fatty acid. Pharmacokinetics of berberine 8998 was conducted on SD rats.Results - Berberine8998 significant lowered the total cholesterol, triglycerides (TG) and LDL-c levels in hamsters. Bioinformatics revealed that berberine and berberine8998 shared similar metabolic pathways where fatty acid metabolism was the most dominant one. Western blot validation results showed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1), Long-chain-fatty-acid—CoA ligase 1 (ACSL1) a protein involved in fatty acid metabolism, expressed differently in berberine8998 group comparing with both model group and berberine treatment group. Further biochemistry results showed that berberine8998 significantly lowered the non-esterified fatty acid (NEFA), which may lead to the reduction of TG levels in berberine8998 treatment groups and the difference in proteomics. Pharmacokinetic study showed that berberine8998, could remarkably improve absorption by 6.7 times, comparing with berberine.Conclusion - These findings suggest that berberine8998 lowers both cholesterol and lipid with different mechanisms from berberine and is a promising therapeutic candidate for treating hypercholesterolemia and obesity.

UR - https://www.nature.com/aps/

U2 - 10.1038/aps.2017.200

DO - 10.1038/aps.2017.200

M3 - Article

VL - 39

SP - 1473

EP - 1482

JO - Acta Pharmacologica Sinica

T2 - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

ER -

ID: 8846637